Literature DB >> 28885076

Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer.

Luiza Ana Maria Olteanu1, Fréderic Duprez1, Wilfried De Neve1,2, Dieter Berwouts3, Tom Vercauteren1, Wouter Bauters4, Philippe Deron5, Wouter Huvenne5, Katrien Bonte5, Ingeborg Goethals3, Julie Schatteman1, Werner De Gersem2.   

Abstract

BACKGROUND: To identify predictive factors for the development of late grade 4 mucosal ulcers in adaptive dose-escalated treatments for head-and-neck cancer.
MATERIAL AND METHODS: Patient data of four dose-escalated three-phase adaptive dose-painting by numbers (DPBN) clinical trials were analyzed in this study. Correlations between the development of late grade 4 ulcers and factors related with the treatment, disease characteristics and the patient were investigated. Dosimetrical thresholds were searched among the highest doses received by 1.75 cm3 (D1.75cc) of the primary gross tumor volume (GTVT) and the corresponding normalized isoeffective dose (NID21.75cc, with a reference dose of 2Gy/fraction and α/β of 3 Gy).
RESULTS: From 39 studied patients, nine developed late grade 4 mucosal ulcers. The continuation to either smoke or drink alcohol after therapy was the factor that showed a strong (eight out of nine patients) association with the occurrence of grade 4 ulcers. Six of the patients who continued to smoke or/and drink had D1.75cc and NID21.75cc above 84 Gy and 95.5 Gy, respectively. Seven of the patients with grade 4 had the dose levels above these thresholds, but even if the D1.75cc threshold was significant in the prediction of late grade 4 ulcers, it could not be considered as the only contributing factor.
CONCLUSIONS: The search for patterns provided strong reasons to apply a dosimetrical threshold for the peak-dose volume of 1.75 cm3 as a preventive measure for late grade 4 mucosal ulcers. Also, patients that continue to smoke or drink alcohol after therapy have increased risk to develop late mucosal ulcers.

Entities:  

Mesh:

Year:  2017        PMID: 28885076     DOI: 10.1080/0284186X.2017.1364867

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

Review 1.  Adaptive radiotherapy for head and neck cancer.

Authors:  Howard E Morgan; David J Sher
Journal:  Cancers Head Neck       Date:  2020-01-09

2.  Robust maximization of tumor control probability for radicality constrained radiotherapy dose painting by numbers of head and neck cancer.

Authors:  Eric Grönlund; Erik Almhagen; Silvia Johansson; Erik Traneus; Anders Ahnesjö
Journal:  Phys Imaging Radiat Oncol       Date:  2019-12-09

3.  Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy.

Authors:  Lisanne V van Dijk; Steven J Frank; Ying Yuan; Brandon Gunn; Amy C Moreno; Abdallah S R Mohamed; Kathryn E Preston; Yun Qing; Michael T Spiotto; William H Morrison; Anna Lee; Jack Phan; Adam S Garden; David I Rosenthal; Johannes A Langendijk; Clifton D Fuller
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-11

4.  Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study.

Authors:  Laura Grocutt; Claire Paterson; Ronan M Valentine
Journal:  Radiat Oncol       Date:  2022-02-05       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.